Reliability of Supply for Patients

Committed to ensuring a reliable, consistent supply of medicines to patients.

As drug shortages become a growing global concern,1 Amgen has identified key practices to help mitigate risk in supply to patients.

Shortages of prescription medicines are a growing problem around the world and can have a significant impact on patients and healthcare providers. Shortages have forced healthcare providers to ration drugs,2 delay critical treatments,3 substitute drugs with less efficacious or more expensive medicines or even use alternative suppliers.4 As identified by the FDA, quality, manufacturing, and capacity issues are major reasons for many of these drug shortages.5

Amgen has developed a multifaceted approach to help prevent drug shortages and employs risk management tactics that involve a continuous process of identifying, preventing, and responding to risks holistically.6 Beyond compliance with current good manufacturing practices (cGMP) and a robust quality management system, Amgen takes extra steps to help ensure a reliable supply to every patient, every time. As a first step, Amgen invests in inventory management at multiple points in the supply chain to mitigate potential risks of disruptions to supply (e.g., natural disasters). Additionally, Amgen maintains appropriate levels of raw materials by diversifying suppliers of sourced raw materials and storing high-risk raw materials in multiple geographical locations to safeguard their availability. By managing relationships with suppliers to ensure that raw materials requirements are understood and shared between both parties, Amgen is able to access high-quality raw materials to minimize reprocessing and potential product manufacturing issues, and help ensure consistent product quality.7

Amgen implements product security programs to help ensure reliable supply of its medicines to patients

amgen manufacturing:

Significant investments in manufacturing to ensure reliable supply

  • $800 million invested from 2005-2011
  • Additional $800 million investment planned from 2012-2016

Eight manufacturing plants around the globe

  • Multiple redundancies help to ensure our medicines reach patients reliably